Yes, patients with a porcine aortic valve replacement can safely use Viagra or Cialis
Patients with bioprosthetic (porcine) aortic valve replacement can safely use phosphodiesterase-5 inhibitors (sildenafil/Viagra or tadalafil/Cialis) provided they are not taking nitrates and meet cardiovascular safety criteria for sexual activity. The presence of a bioprosthetic valve itself is not a contraindication to PDE5 inhibitor use.
Key Safety Requirements
Absolute Contraindications
The only absolute contraindication relevant to valve patients is concurrent nitrate use 1, 2:
- Do not use if taking any form of nitrates (nitroglycerin, isosorbide mononitrate/dinitrate, long-acting nitrates)
- Sildenafil and vardenafil: avoid nitrates for ≥24 hours after use
- Tadalafil: avoid nitrates for ≥48 hours after use (due to longer half-life of 17.5 hours) 1, 3
- If emergency nitrate administration becomes necessary, at least 48 hours must elapse after the last Cialis dose 2
Cardiovascular Risk Stratification
Before prescribing, assess whether the patient can safely engage in sexual activity (approximately 3-5 metabolic equivalents of exertion) 1, 4:
Low-Risk Patients (PDE5 inhibitors are safe) 4:
- Mild valvular disease (including mild bioprosthetic valve dysfunction)
- Controlled hypertension
- Post-successful valve replacement with good function
- Asymptomatic with <3 cardiac risk factors
- Able to achieve 4-5 METs on exercise testing without symptoms
High-Risk Patients (defer treatment until stabilized) 4:
- Moderate-to-severe valvular disease
- NYHA Class III-IV heart failure
- Uncontrolled hypertension or hypotension (<90/50 mmHg)
- Recent MI (<2 weeks) or stroke (<6 months)
- Unstable angina
- High-risk arrhythmias
Specific Considerations for Bioprosthetic Valve Patients
Why Bioprosthetic Valves Are Not a Contraindication
The FDA labeling for Cialis specifically mentions that patients with left ventricular outflow obstruction (e.g., aortic stenosis) can be sensitive to vasodilators 2. However, this refers to native severe aortic stenosis, not to patients with well-functioning bioprosthetic valves. A properly functioning porcine valve has relieved the obstruction.
The Princeton Consensus guidelines explicitly state that patients with mild valvular disease are at low risk 4. Post-valve replacement patients with good valve function fall into this category.
Drug Interactions to Monitor
Exercise caution with 5:
- CYP3A4 inhibitors (diltiazem, verapamil) - may increase PDE5 inhibitor levels and hypotension risk
- Grapefruit juice or excessive alcohol
- Alpha-blockers or other antihypertensives - additive blood pressure lowering
Practical Prescribing Approach
- Verify no nitrate use - this is non-negotiable
- Assess valve function - ensure bioprosthetic valve is functioning well without significant stenosis or regurgitation
- Evaluate cardiovascular status - confirm patient is low-risk per above criteria
- Consider exercise testing if uncertain about functional capacity - target ≥4-5 METs without ischemia 4, 6
- Start with standard dosing 7, 8:
- Sildenafil: typically 50 mg, adjust to 25-100 mg
- Tadalafil: 10 mg on-demand or 2.5-5 mg daily
- Educate patient about:
- Taking medication 1 hour before sexual activity (sildenafil) or timing flexibility with tadalafil
- Absolute prohibition of nitrate use
- Seeking emergency care if chest pain develops (nitrates cannot be given for 24-48 hours)
- Stopping sexual activity if symptoms develop
Common Pitfalls to Avoid
- Don't confuse bioprosthetic valves with mechanical valves - the anticoagulation requirements differ, but neither is a contraindication to PDE5 inhibitors
- Don't assume all cardiac patients are high-risk - most post-valve replacement patients with good function are actually low-risk 4
- Don't forget to ask about nitrate use - including sublingual nitroglycerin "as needed" preparations
- Don't overlook over-the-counter supplements - some contain nitrates or interact with PDE5 inhibitors
The 2025 AHA/ACC hypertension guidelines confirm that PDE5 inhibitors are safe and effective when administered with antihypertensive medications, with the critical exception of nitrates 5. The 2023 chronic coronary disease guidelines emphasize that the primary concern is nitrate co-administration, not the presence of structural heart disease per se 1.